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Summary: The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a 
combination of arterial and/or venous thrombosis, pregnancy morbidity, and the persistent presence of 
circulating antiphospholipid antibodies (aPL). APS has been described as primary APS when it occurs in the 
absence of any features of other autoimmune disease, and as secondary in the presence of other 
autoimmune diseases, mainly systemic lupus erythematosus (SLE). There is a well-known link between SLE 
and APS; 40% of SLE patients have aPL, and, in turn, some, but only a minority of patients with APS, 
eventually will develop features of SLE. Because SLE and APS can target the kidneys independently or at the 
same time, discriminating between inflammatory or thrombotic lesions is crucial in planning therapy. We 
provide an overview of the renal manifestations associated with the presence of aPL in patients with SLE, 
and discuss the impact of aPL in selected scenarios such as lupus nephritis, end-stage renal disease, and 
pregnancy. 
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The antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by a combination of 
arterial and/or venous thrombosis and the persistent presence of circulating antiphospholipid antibodies 
(aPL).1 APS has been described as primary APS when it occurs in the absence of any features of other 
autoimmune disease, and as secondary in the presence of other autoimmune diseases, mainly systemic 
lupus erythematosus (SLE). Because SLE and APS can target the kidneys independently or at the same time, 
discriminating between inflammatory and thrombotic lesions is crucial in planning an adequate therapeutic 
strategy. The incidence of kidney involvement in SLE ranges from 30% to 50%, depending on the definition 
of abnormal renal function, and represents a severe organ manifestation that is associated with significant 
patient morbidity and mortality.2,3 Although all renal compartments (glomerular, tubulointerstitial, and 
vascular) can be injured in SLE, the term lupus nephritis refers specifi- cally to immune-complex mediated 
glomerulonephritis. Lupus nephritis (LN) presents with diverse clinical and histologic manifestations. 
However, the main driver of LN remains the immune system and therefore the main therapeutic approach 
is immunosuppression.4 Among SLE patients, the prevalence of aPL ranges from 30% to 40%.5 
Approximately 50% of patients with both SLE and aPL will develop APS during longterm (10-20 y) follow-up 
evaluation.5 The presence of aPL in patients with SLE and LN has been shown to be associated with 
increased mortality and a poorer prognosis, and renal APS requires treatment beyond 
immunosuppression.6 In this review we describe the role of aPL/APS in kidney injury in SLE, and focuses on 
state-of-the art treatment and future therapies of APS. aPL SPECIFICITIES AND THROMBOSIS APS has been 
known for over three decades and advances in research have identified the coagulation system and the 
immune system as key players underlying the clinical manifestations of the syndrome.5 The persistent 
presence of aPL is crucial for the classification of APS. aPL are recognized as a heterogeneous group of 
antibodies directed against anionic phospholipids or protein-phospholipid complexes. Laboratory tests 
aimed to identify aPL include solid-phase immunoassays (enzyme-linked immunosorbent assay) to detect 
anticardiolipin (aCL) and anti-β2 glycoprotein 1 (aβ2GPI) antibodies, and functional assays to detect lupus 
anticoagulant (LAC). LAC has the ability to interfere with phospholipid-dependent coagulation reactions. 
The first international consensus statement on classifi- cation criteria for APS was developed in 1998 in 
Sapporo, Japan. Eight years later the consensus criteria were updated.1 According to the current 
classification criteria of APS (Table 1), at least one clinical manifestation is needed. This may include any 
vascular thrombosis and/or pregnancy morbidity in combination with a positive laboratory test, including 
LAC, aCL, or aβ2GPI, detected at least twice 12 weeks apart. The syndrome can present with a variety of 
clinical manifestations caused by thrombosis of any vessel. Deep vein thrombosis and pulmonary embolism 
are the most frequent features in the venous vasculature.6 The most common arterial manifestations are 
neurologic, such as transient ischemic attacks or strokes, or dermatologic manifestations, such as livedo 
reticularis, seen in 20% of APS patients. aPL-mediated placental dysfunction, which partially, but not 
entirely, can be explained by thrombosis, may cause intrauterine growth restriction, preeclampsia, 
intrauterine fetal death, or placental abruption.7 Thromboses are the main cause of renal involvement in 
APS and can occur at any level within the renal vasculature. These thrombotic events can lead to various 
manifestations that reflect the site and size of the involved vessel. A substantial body of evidence supports 
the inclusion of aPL-related nephropathy in the classification criteria for definitive APS.8 aPL ANTIBODIES 
AND THROMBOSIS IN VIVO A two-hit hypothesis for the pathogenesis of APS has been suggested. This is 
based on the fact that the presence of aPL in the circulation sometimes, but not always, leads to 
thrombotic events. Therefore, the presence of aPL is necessary but not sufficient for thrombi formation in 
vivo. This hypothesis implies that the presence of aPL (the first hit) does not itself cause a thrombus, but 
increses the risk of any thrombotic events when another prothrombotic factor is added (the second 
hit).9,10 Thus, according to this model, the presence of aPL creates a prothrombotic state, while the second 
hit leads to thrombus formation. In this regard, it is useful to speculate on the reported association 
between an acute thrombotic event and a recent or concomitant infectious process in APS patients, or with 
a traumatic or inflammatory stimulus in experimental models.11 Furthermore, a genetically determined 
thrombophilic diathesis, or ability to mount a prompt inflammatory response, may enhance the thrombotic 
risk of subjects with aPL further. The proposed pathophysiological mechanisms underlying aPL-mediated 
thrombosis in APS have been divided into two main types.10,12 First, aPL may act in vivo by disrupting the 
normal balance between procoagulants and anticoagulants. Second, aPL may interact with specific cell 
surface receptors (proteins and/or lipids), inducing downstream signals that up-regulate procoagulant cell 
surface proteins.13 
For example, it appears that the expression of tissue factor, the main activator of the coagulation system, is 
increased on endothelial cells and monocytes in APS.13 aPL specifically affects platelets, endothelial cells, 
and monocytes, at least in part through binding to β2GPI expressed on cell membranes.13 aPL also affects 
plasma coagulation regulatory proteins, coagulation cascade components (such as prothrombin, 
antithrombin, proteins C and S, factor X), and fibrinolysis.10,13 Other processes suggested to play a role in 
aPLinduced thrombosis include conformational and posttranslational redox modifications of β2GPI, 
decreased activity of endothelial nitric oxide synthase, and complement activation. Traditional 
cardiovascular risk factors also may contribute to the aPL-induced prothrombotic state and are found in 
more than 50% of patients with APS. These risk factors are of particular relevance given their modifiable 
nature. We recently reported that arterial hypertension and hyperlipidemia, together with different aPL 
specificities, are independent risk factors for thrombotic events in APS.14 APS AND RENAL 
MANIFESTATIONS As mentioned previously, APS is an autoimmune disease characterized by the presence 
of aPL, arterial or venous thrombosis, and/or pregnancy complications. Any organ can be affected in this 
disorder; thus, the range of clinical features is extremely wide (Table 2). 
Vessels of all sizes may be affected by thrombus formation, and the vascular pathologic appearance 
consistently has been of bland occlusion without inflammatory infiltrates in the vessel walls.15 Amigo et 
al16 first described renal involvement in APS in 1992. Since then, a spectrum of renal thrombotic 
manifestations has been described in association with aPL, such as renal artery stenosis, renal infarction, 
renal vein thrombosis, and acute or chronic thrombotic microangiopathy (TMA)17,18 (Table 3). A distinct 
clinical entity, the so-called, “aPL nephropathy,” has been described.19,20 The clinical and histologic 
manifestations of aPL nephropathy reflect the renal vessels affected and include ischemic glomeruli and 
thrombotic lesions, without glomerular or arterial immune deposits on immunofluorescence.21 APS 
NEPHROPATHY The term APS nephropathy (APSN) refers to renal damage caused by vascular lesions in the 
glomeruli, arterioles, and/or interlobular arteries in patients with persistently present aPL. APSN has been 
described in aPL carriers, in patients with primary APS, and in patients with secondary APS (especially in 
patients with SLE), in whom it can coincide with the presence of LN.22 APSN lesions can present as acute 
lesions (so-called TMA) and/or chronic arteriosclerosis, tubular thyroidization, fibrous intimal hyperplasia, 
and focal cortical atrophy.16,23 
Clinical Features APSN may manifest with a nephritic or nephrotic picture, acute or chronic renal failure, 
hypertension, hematuria, and (mostly mild) proteinuria.16,19 The diagnosis of APSN can be a particular 
challenge in patients with underlying SLE, and should be supported by a kidney biopsy. Differential 
Diagnosis When confronted with a clinical picture of systemic or intrarenal platelet aggregation and 
thrombocytopenia in combination with microvascular fragmentation of erythrocytes resulting in ischemic 
end-organ injury, the main differential diagnosed in addition to APS include other causes of TMA, such as 
thrombotic thrombocytopenic purpura or hemolytic uremic syndrome.23 Severe thrombocytopenia and 
anemia are observed more commonly in thrombotic thrombocytopenic purpura/hemolytic uremic 
syndrome and the presence of peripheral blood schistocytes rarely is observed in APS. A useful tool to 
distinguish between APS and other possible causes of TMA is a test for aPL.24 The clinical utility of aPL 
assays for autoantibodies other than those assessed routinely, such as aCL and aβ2GPI, is under debate.25 
Indeed, current lines of research are examining the usefulness of testing for new aPL specificities (such as 
antiprothrombin antibodies) in helping to identify APS in patients with thrombosis and/or pregnancy 
morbidity, particularly in patients who repeatedly are negative for the currently used tests.25 Catastrophic 
APS (CAPS) is a particularly severe form of APS, and the kidney is the most commonly involved organ. A 
definitive diagnosis of CAPS requires the following: (1) clinical evidence of involvement of three or more 
organ systems in a period of less than a week, (2) histopathologic evidence of small-vessel occlusion in at 
least one organ system, and (3) laboratory confirmation of the presence of aPL, usually in high titers.26 
CAPS is associated with a high mortality rate and is therefore an important differential to consider.26 
Histologic Findings Histologically, vaso-occlusive lesions caused by acute microthrombi and chronic vascular 
lesions including intimal hyperplasia, fibrous occlusions with focal atrophy, and recanalization of occluded 
vessels can be found27 (Fig. 1). Ultrastructural changes may show the co-existence of glomerular basement 
membrane reduplication and glomerular basement membrane wrinkling.16 TMA is a common distinct 
histologic finding in APSN, although it is not an exclusive finding in APS and not all patients present with a 
full picture of TMA. The formation of glomerular microthrombi has also been described in connection with 
aPL.28,29 Among patients with SLE and diffuse proliferative glomerulonephritis, up to 20% to 30% were 
shown to have glomerular microthrombi, and they have been described as a strong predictor of glomerular 
sclerosis and subsequent poor renal outcome.29,30 This raises the question of whether microthrombi 
formation can be regarded as part of the TMA spectrum. Zheng et al29 reported an association of the 
presence of glomerular microthrombi with detection of LAC and aβ2GPI in SLE patients. In the cohort of 
124 LN patients studied by Zheng et al,29 serum complement C3 levels were lower, and C3 and C1q staining 
was more intense compared with patients without glomerular microthrombi. In a retrospective analysis of 
114 renal biopsy specimens from lupus patients, Daugas et al19 showed that APSN occurred in 32% of 
patients in addition to and independently from lupus nephritis. APSN statistically was associated with aPL, 
mainly LAC and with extrarenal manifestations of APS, such as arterial thrombosis and obstetric fetal loss. 
In their cohort, no association between APSN and venous thrombosis was found. The investigators 
concluded that APSN was an independent risk factor favoring an increased prevalence of hypertension, an 
increased serum creatinine level, and an increased prevalence of interstitial fibrosis in SLE.19 Tektonidou et 
al18 studied the prevalence, clinical associations, and long-term outcomes of APSN. APSN was documented 
in approximately two thirds of SLE patients with secondary APS. The investigators concluded that LAC 
and/or aCL was associated with TMA, but not with LN, and hence that APS nephropathy occurred almost 
exclusively in patients with aPL, confirming the important role of aPL in the pathogenesis of APS 
nephropathy. In line with Daugas et al,19 they found an association with hypertension, increased serum 
creatinine levels, and histologic progression, all of which were associated with a poor renal outcome. aPL in 
Lupus Nephritis APS contributes significantly to the renal morbidity in patients with lupus nephritis.19,31 
Moroni et al32 found that the presence of aPL in LN patients increased the risk of vascular and obstetric 
complications, and showed a strong association between aPL antibodies and prognosis in patients with LN. 
In their cohort of 111 patients, aPL antibody positivity, high plasma creatinine level at presentation, and 
chronicity index were independent predictors of chronic renal function deterioration. These results are in 
line with Pérez Velásquez et al,33 who examined a cohort of 600 patients with SLE. This group found not 
only that LAC and anticardiolipin were more prevalent, but also that more than half of patients with 
secondary APS had renal disease (56%) and 43% showed typical features of APS on renal biopsy. The 
significance of APSN is reflected in the longterm outcome of these patients. Tektonidou et al18 studied SLE 
patients (with or without aPL) to determine the prevalence and long-term outcome of APSN, as well as the 
histologic evolution of APSN lesions on serial kidney biopsy specimens. In their cohort of 151 patients, APSN 
was documented, in addition to and independently from lupus nephritis, in almost 40% of patients with aPL 
compared with only 3 of 70 (2.1%) patients without aPL, suggesting a critical role of aPL in the pathogenesis 
of APSN. Compared with patients without APSN, patients with APSN had a higher frequency of 
hypertension and increased serum creatinine levels at the time of kidney biopsy, and developed 
progression of histologic lesions, all of which were associated with a poor renal outcome.18 SLE, APS, and 
Pregnancy SLE commonly affects women during their childbearing years, and pregnancy is therefore an 
important topic. SLE has a tendency to flare during pregnancy and consequently may impact renal function 
with possible long-term consequences such as end-stage renal disease. Pregnancy counseling to ensure 
disease remission, close follow-up evaluation during pregnancy, and post-partum surveillance play a major 
role in improving pregnancy outcomes.34 The presence of aPL is a well-documented risk factor for 
pregnancy morbidity, including recurrent abortions, premature delivery, intrauterine growth restriction, 
and preeclampsia, and can be found in 25% of SLE pregnancies.35 Post-partum renal failure in association 
with the presence of aPL was described in the 1980s by Kincaid-Smith et al.36,37 A recent metaanalysis by 
Smyth et al35 confirmed a positive association between the presence of aPL and hypertension in 
pregnancy, premature birth, and recurrent miscarriages. A cohort of 1842 patients and 2751 pregnancies 
was examined. Maternal complications included lupus flare (25.6%), hypertension (16.3%), nephritis 
(16.1%), preeclampsia (7.6%), and eclampsia (0.8%). Fetal complications included spontaneous abortion 
(16.0%), stillbirth (3.6%), neonatal deaths (2.5%), and intrauterine growth restriction (12.7%), with a 
premature birth rate of 39.4%.35 Treatment The treatment of asymptomatic aPL carriers without 
underlying autoimmune disease remains controversial. However, a recent consensus document 
emphasized that there is no role for primary thromboprophylaxis with low-titer aPL or intermittent aPL 
positivity (Table 4).38 In asymptomatic aPL carriers with underlying autoimmune conditions, especially SLE, 
primary thromboprophylaxis should be considered because this condition itself may be thought of as an 
additional risk factor for thrombosis. Therefore, primary thromboprophylaxis with low-dose aspirin (75-100 
mg/day) could be considered in all patients with an underlying systemic autoimmune condition and 
persistent aPL at medium-high titers (IgM or IgG phospholipid units 4 40 GPL or MPL or 4 99th percentile). 
In patients with SLE specifically and persistently positive aPL, primary thromboprophylaxis including low-
dose aspirin (75- 100 mg/day) and/or hydroxychloroquine (200-400 mg/day) is recommended. This 
suggestion is based on retrospective studies that have shown that hydroxychloroquine appears to protect 
SLE patients, especially those with aPL, against thrombosis.39 Although no study has investigated 
specifically whether the addition of antiplatelet agents offers additional protection, aspirin also may be 
considered in the setting of primary thromboprophylaxis.40 Given the general recommendation of 
hydroxychloroquine administration in most patients with SLE, the addition of low-dose aspirin should be 
decided on an individual basis. The addition of lowdose aspirin may be appropriate in selected cases, such 
as patients with a high-risk aPL profile (eg, triple positivity for lupus anticoagulant, aCL and aβ2GPI), other 
concomitant cardiovascular risk factors, and/or SLE patients with a history of obstetric APS. In patients with 
previous thrombosis (regardless of any underlying autoimmune disease) anticoagulation with a vitamin K 
antagonist (international normalized ratio, 2.0-3.0) is required as long-term secondary 
thromboprophylaxis.41,42 Patients with arterial events or cases of recurrent thrombotic events despite 
ongoing treatment may require high-intensity treatment (international normalized ratio, 3.0-4.0) with 
warfarin.43 With regard to the management of renal artery stenosis, treatment with antihypertensive 
drugs, antiaggregation agents, and anticoagulants have been reported to be effective. Sangle et al41 
analyzed 14 hypertensive APS patients with renal artery stenosis who received oral anticoagulation for 
more than 1 year and reported the beneficial effects of their approach on blood pressure control and renal 
function. The treatment for APSN is based on anticoagulation. Steroids, hydroxycloroquine, and some 
immunosuppressive agents occasionally have been reported to reduce the titer of aPL, but their role in 
reducing the risk of thrombosis has not yet been proven. A few studies evaluating the role of 
immunosuppressants on primary APSN have reported favorable effects.42,44 The long-term use of 
intravenous immunoglobulin also has been reported in very selected cases of primary relapsing APS despite 
standard treatment.45 New oral anticoagulants such as dabigatran, apixaban, and rivaroxaban now are 
available. They have been shown to be effective in the management of venous thromboembolism and they 
do not require laboratory monitoring. Preliminary experience supporting the use of new oral anticoagulants 
in patients with APS were reported recently.46 A trial to assess the efficacy and safety of rivaroxaban in APS 
currently is underway.47 B-cell depletion with rituximab also has been suggested for selected cases of APS, 
mainly in the presence of severe thrombocytopenia.48 Recently, Erkan et al49 designed a 12-month, phase 
II pilot rituximab study, including adult aPL-positive patients with thrombocytopenia, cardiac valve disease, 
skin ulcer, aPL nephropathy, and/or cognitive dysfunction. A potential role of eculizumab, an anti-C5 
antibody, in selected cases of APS also has been proposed. However, available evidence still is based on 
experimental APS models or anecdotal cases.50,51 
Take Home Messages 
The following points should be kept in mind. ı 
 In patients affected by APS, both primary and associated with other autoimmune diseases such as SLE, 
the kidney is a major target organ. ı 
 Renal involvement in APS is a well-recognized manifestation of the syndrome and is characterized by the 
occurrence of thrombosis, potentially involving any site of the kidney vasculature. 
 In SLE, APSN can co-exist with LN. A biopsy is mandatory for a differential diagnosis. ı 
 Because of the clinical and histologic similarities between APSN and other microangiopathies, an aPL test 
is useful to distinguish between possible causes. ı 
 The presence of Lupus Anticoagulant and/or aCL in SLE patients can be considered a risk factor for poor 
renal outcome even in the absence of LN. ı 
 CAPS must be considered in the differential diagnosis of APSN because it is associated with high mortality 
and must be treated aggressively. ı 
 During pregnancy the presence of aPL is associated with a higher risk of morbidity including hypertension, 
nephritis, preeclampsia, and eclampsia. ı 
 The use of hydroxychloroquine is recommended in patients with aPL associated with SLE even in the 
absence of APS. 
 Low-dose aspirin can be useful in patients with a higher risk of thrombosis (eg, triple positivity for aPL). ı 
 Therapeutic approaches for renal involvement in APS focuses on anticoagulation with long-term warfarin. 
ı 
 Presently, there are not sufficient data regarding the use of new oral anticoagulants in patients with 
APSN. ı 
 Rescue therapies, including intravenous immunoglobulins, rituximab, or eculizumab can be attempted in 
refractory cases. 
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Figure 1. APS-associated nephropathy. (A) Hematoxylin-eosin stain. Intracapillary thrombi in the glomerulus 
on the left. The afferent arteriole is occluded entirely by a fibrin thrombus (black arrow). (B) Same stain. 
Fibrinoid necrosis and mucoid intimal edema in the intima of an arteriole (red arrow) with fragmented red 
blood cells. The interstitium around the arteriole is edematous. (C) Same stain. Thrombi occluding 
peritubular capillaries (black arrow). Interstitial edema, hemorrhage, and acute tubular injury might be 
present depending on the severity of the acute ischemic injury. (D) Large intravascular thrombus at the 
vascular pole of a glomerulus is red under trichrome staining (black arrow). (E) Direct immunofluorescence 
showing positive staining for fibrinogen in glomerular capillary lumina and at the vascular pole (white 
arrows). (F) At ultrastructural examination fibrin occludes the capillary lumen. Endothelial cells have lost 
fenestration and podocytes show extensive foot process effacement. (G) In chronic disease, double 
contours without interposition of electron dense immune complexes can be seen (white arrow). Platelets 
are seen in capillary lumina in both acute and chronic phases (black circle). Podocytes often are injured and 
show foot process effacement (black arrows). Figure reprinted with permission from Sciascia et al.1 
 
  
 
 
